Eric Honroth reports a stock award at Angiodynamics
By AlphaYouPublished Form 4
Honroth Eric
Reporting filer
Eric Honroth reports a stock award, not an open-market purchase or sale, in Angiodynamics Inc. Form 4 filed Nov 4, 2026 lists 3 entries.
- Disclosed
- Nov 4, 2026
Reported details
3 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Honroth Eric | 2026-11-02 | A | Grant or award | 62928 | 0 | 62,928 | 2 days | Filed terms
|
| Common Stock | Honroth Eric | 2026-11-02 | A | Grant or award | 38265 | 0 | 101,193 | 2 days | Filed terms
|
| Performance Right (derivative) | Honroth Eric | 2026-11-02 | A | Grant or award | 62928 | 0 | 62,928 | 2 days | Filed terms
|
Common Stock
- Owner
- Honroth Eric
- Date
- 2026-11-02
- Code
- A
- Action
- Grant or award
- Quantity
- 62928
- Price
- 0
- Following holdings
- 62,928
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-02
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: false
- transaction Shares: 62928
- id: F1
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 62928
- direct Or Indirect Ownership: D
Common Stock
- Owner
- Honroth Eric
- Date
- 2026-11-02
- Code
- A
- Action
- Grant or award
- Quantity
- 38265
- Price
- 0
- Following holdings
- 101,193
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-02
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: false
- transaction Shares: 38265
- id: F2
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 101193
- direct Or Indirect Ownership: D
Performance Right (derivative)
- Owner
- Honroth Eric
- Date
- 2026-11-02
- Code
- A
- Action
- Grant or award
- Quantity
- 62928
- Price
- 0
- Following holdings
- 62,928
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Performance Right
- id: F3
- transaction Date: 2026-11-02
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: false
- transaction Shares: 62928
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- id: F3
- id: F3
- underlying Security Title: Common Stock
- underlying Security Shares: 62928
- shares Owned Following Transaction: 62928
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Honroth Eric: President and CEO, Director.
- F1: The acquisition of 62,928 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents 62,928 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments consistent with awards granted to other executive officers of the Company and beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued employment through each applicable vesting date.
- F2: The acquisition of 38,265 shares of Common Stock represents 38,265 restricted stock units granted to replace equity compensation the Reporting Person forfeited at his prior employer, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in two equal annual installments, such that 50% of the restricted stock units will vest on each of November 2, 2027 and November 2, 2028, subject to the Reporting Person's continued employment through each vesting date.
- F3: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned, if at all, based on a combination of the Company's revenue, adjusted EBITDA, and total shareholder return ("TSR") relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement to the extent relative TSR over the three-year performance period exceeds the 75th percentile or is below the 25th percentile (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.
Original sources
Prepared automatically from public filing data. Report a correction.